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Metastasis is a major hurdle to the efficient treatment of cancer, accounting for the great
majority of cancer-related deaths. Although several studies have disclosed the detailed
mechanisms underlying primary tumor formation, the emergence of metastatic disease
remains poorly understood. This multistep process encompasses the dissemination of
cancer cells to distant organs, followed by their adaptation to foreign microenvironments
and establishment in secondary tumors. During the last decades, it was discovered that
these events may be favored by particular metabolic patterns, which are dependent on
reprogrammed signaling pathways in cancer cells while they acquire metastatic traits. In
this review, we present current knowledge of molecular mechanisms that coordinate the
crosstalk between metastatic signaling and cellular metabolism. The recent findings
involving the contribution of crucial metabolic pathways involved in the bioenergetics
and biosynthesis control in metastatic cells are summarized. Finally, we highlight new
promising metabolism-based therapeutic strategies as a putative way of
impairing metastasis.
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Metastasis is the main critical issue in cancer progression, being responsible for 90% of cancer-
related deaths (1). The way cancer cells manage to detach from the primary tumor, migrate, invade,
and follow the metastatic routes (e.g. hematogenous, lymphatic, serous, direct and nervous) depends
on several forces and stresses. The transformation a cancer cell undergoes to get free from the tumor
and gain migratory and invasive capacity, requires a multitude of orchestrated molecular changes
(2). The most well-known metastatic route is the hematogenous and carcinomas, which account for
more than 80% of all the malignant neoplasias, have been the most studied in the metastatic context
(3). This metastatic cascade is composed by the following steps: cancer cells release from the
primary tumor, local invasion, vessels intravasation, trip on the blood circulation, vessels
extravasation, and secondary organs colonization (4) (Figure 1).
The epithelial-to-mesenchymal transition (EMT) in cancer cells is an important event to allow
these cells to invade and intravasate the vasculature. The morphological alterations necessary for aJune 2021 | Volume 11 | Article 6568511
Hipólito et al. Targeting Metabolism in Metastatic Cellsstatic carcinoma cell to become migratory involve the
replacement of molecules characteristic of epithelial
architecture by mesenchymal molecules. The best known EMT
markers are the loss of E-cadherin expression, an epithelial
adhesion molecule (adherens junction), and the gain of
vimentin expression, a protein from the intermediate filaments
of the cytoskeleton (5, 6). The metastatic capacity of cancer cells
must be addressed considering the molecular changes exhibited
by the cancer cell, and the composition and physical properties of
the substrate (matrix) to be invaded. The local invasion capacity
is crucial in the metastatic cascade since it allows detached cancer
cells to infiltrate the stroma and enter the bloodstream (7).
Invadopodia are subcellular F-actin-rich structures present in
invasive cancer cells, composed of several signaling, cytoskeletal,
adhesion and matrix degradation proteins, that are mainly
responsible for offering traction for these cells and degrading
the ECM (8, 9) (Figure 1). The ECM proteins play an important
role as a network for sharing signaling molecules and (in)organic
compounds and as a supportive scaffold for the organization of
cells within tissues and organs (10, 11). However, ECM proteins
are themselves an important complex of insoluble ligands
involved in signaling activation, mainly through the interaction
with integrins (12). The stiffness and resistance of stromal ECM
are dependent on the relative composition of ECM protein types
(3, 13, 14). Our team and others have published that certain ECM
proteins, such as fibronectin and different types of collagen and
laminin, can favor the cancer metastatic process (15–18).Frontiers in Oncology | www.frontiersin.org 2Intravasation is defined as the ability of cancer cells to enter
the vessels and follow the bloodstream (4, 19, 20). Once in the
bloodstream, cancer cells face a hostile environment and are
exposed to mechanical stress, shear forces, and to the presence of
immune cells and oxidative stress, which may compromise their
successful arrival at the distant metastasis site (21, 22). As an
escape to those adversities, cancer cells establish a vital
partnership with platelets during this transition. Cancer cells
release soluble factors and activate platelets, which sheath them
in a clot, impeding cytolysis and assuring their protection against
adversities (23). Platelets by themselves have pro-metastatic
effects by inducing EMT-like status and increase cancer cell
invasive ability and extravasation (22, 24, 25). Therefore, the next
tricky step of the metastatic cascade is the extravasation of these
cells from the vessels into the nearby tissue (21). This process
depends on the adhesion of these cells to endothelium and
modulation of the endothelial barrier, promoting their
extravasation across the vessels’ wall. Usually, tumor cells get
physically arrested in small capillaries, where they migrate across
the endothelial barrier. This occurs by transendothelial
migration, either by paracellular migration, in which tumor
cells cross between adjacent endothelial cells, leading to cellular
rearrangements; or by transcellular transendothelial migration,
in which tumor cells migrate directly across the endothelial cell
body (21, 26). During this process, tumor-specific proteins,
including cadherins, integrins and selectins, amongst other
molecules responsible for the adhesion to endothelium have aFIGURE 1 | Hematogenous metastatic route. The metastatic cascade starts with molecular and morphological changes in cancer cells, enabling their release from
the primary tumor. The production of tumor secreted factors (e.g. MMPs) by cancer cells to degrade the extracellular matrix (ECM) (1), helps the gain of migratory
and invasive abilities (2). The metastasizing cancer cells, depending on the cancer type, rely on epithelial to mesenchymal transition (EMT), in which cancer cells
acquires a mesenchymal phenotype through the loss epithelial cell-cell contacts, as E-Cadherin, to facilitate the penetration into the basal membrane. However, in
other scenarios collective or cluster‐based migration and invasion can contribute to cancer cell intravasation independent of EMT. The different phases of the
hematogenous metastatic cascade are: local invasion (1 and 2); intravasation into vessels (3); circulation into the bloodstream (4); extravasion into a distant organ or
tissue (5), and the formation of a secondary tumor in the metastatic niche (6). The metabolic remodeling during the metastatic processes is crucial for the efficient
colonization of cancer cells in distant sites, typically nutrient and oxygen-rich areas, as lungs, liver, bones and brain.June 2021 | Volume 11 | Article 656851
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and managed to survive and colonize a secondary organ,
eventually form distant metastases. Successful colonization
depends on the adaptation and positive interaction of the
tumor cell and the organ’s microenvironment (29). Tumor
cells must rely on a permissive microenvironment to colonize
and, thus, the specific cellular traits may influence the adaptation
of tumor cells to this microenvironment and metabolic
remodeling certainly plays a role in this process.
The metabolic adaptation to the microenvironment is crucial
for a primary tumor to grow locally, invade and metastasize. The
metastatic cancer cells are especially more plastic than
non-metastatic cancer cells, since the latter ones must survive
in the microenvironment where the primary tumor develops and
in the microenvironment of the secondary organ to which
they metastasize.REWIRED METABOLIC TRAITS IN
METASTASIS, A WAY OF SURVIVING
OUTSIDE OF THE PRIMARY TUMOR
Over the last years, cancer metabolism gained an increasing
research interest, since metabolic reprogramming was
considered a hallmark of cancer (30, 31). For a tumor to be
established, it requires a metabolic adaptation to the
microenvironment, allowing the tumor to grow and thrive.
Moreover, metastatic cells require further alterations to the
metabolic profile, once they have to adapt and prosper in the
microenvironment of the metastasized organ (32). In this
section, we will explore metabolic alterations in the main
pathways involved in energy and biomass production upon
metastasis (Figure 2).
Glycolysis
The enzymes hexokinase (HK) 2 and pyruvate kinase (PK) M2
are key enzymes in glycolysis as they define the beginning and
ending of the pathway. HK2 catalyzes the first rate-limiting step
of glycolysis, converting glucose to glucose-6-phosphate, which
may be deviated into the phosphate pentose pathway (PPP); and
PKM2 converts phosphoenolpyruvate to pyruvate, linking
glycolysis to an enormous metabolic network, such as lactate,
tricarboxylic acids, fatty acids and amino acids metabolism (33).
Both enzymes have been associated with metastasis formation,
since their expression is correlated with increased lactate
production (34, 35), concomitant with enhanced motility and
invasive capacity (20). Given the importance of these enzymes in
glycolysis, their knockdown results in impaired glycolysis and
decreased lactate levels, being this associated with decreased
motility and invasion (34, 36). Zhang et al. described c-Src, a
tyrosine kinase, as a regulator of both HK1 and HK2, increasing
their catalytic activity by phosphorylation of their tyrosine kinase
residues, and consequently enhancing glycolysis in HCT116 cell
line (37). c-Src is constitutively activated or present in increased
protein levels in several human cancers (38). Moreover, itsFrontiers in Oncology | www.frontiersin.org 3phosphorylation and activation promotes in vitro cancer cells
migration and invasion, and an increased formation of lung
metastasis in vivo, in a process dependent on both HK1 and HK2
(37). In addition, silencing HK2 in neuroblastoma cells reduces
the growth of xenograft tumors and the incidence of lung
metastases in mice (39). This association seems to be related to
the glycolysis-derived methylglyoxal, a metabolic by-product
known to activate yes-associated protein (YAP) signaling in
breast cancer cells, which is crucial in the upregulation of
genes that promote cell proliferation (e. g. CTGF, CYR61, and
ANKRD1, ERBB4, FOS, AP-1) (40, 41), inhibit apoptosis (e. g.
Bcl-2 family members) (42, 43), and drive EMT (44). In fact,
EMT requires YAP/TAZ (transcriptional co-activator with PDZ-
binding motif) to trigger cancer stemness and metastasis
(45–47).
In pancreatic cancer patients, the upregulation of PKM2 was
related to advanced tumor stage and metastasis (48). The same
was observed in colorectal and gastric cancer patients with
advanced and metastatic disease, who were found to have
augmented levels of PKM2 in their plasma (49). In early stage
breast cancer patients, the levels of circulating miR-122, a
negative regulator of PKM2, can be used to predict metastatic
progression (50). The PKM2 regulatory dynamics by miR-122
seems to result from a crosstalk between cancer cells and non-
malignant cells. Thereby expressing and secreting miR-122,
breast cancer cells control the glucose consumption by non-
malignant cells, which will uptake miR-122 and reduce PKM2
expression, and consequently glycolysis, in such way increasing
glucose bioavailability to be used by cancer cells (51).
Accordingly, the inhibition of miR-122 expression by cancer
cells reduces the incidence of metastasis, whereas miR-122
overexpression increases the metastatic rate (51).
PFKFB3 (6-phosphofructo-2-kinase/ fructose-2 ,6-
biphosphatase 3) expression is increased in cancer and it acts
as an allosteric activator of the glycolytic enzyme
phosphofructokinase 1 (PFK1), stimulating glycolysis (52).
Additionally, PFKFB3 activity is essential for cell proliferation,
as it prompts the cell cycle progression from the G1 to S phase
(52). PFKFB3 is also important in the metastatic cascade since its
expression in endothelial cells, which are hyperglycolytic,
promotes angiogenesis and the formation of cancer typical
leaky vessels, favoring the intravasation and metastatic spread
of cancer cells (53).
The increased rate of glycolysis observed in cancer results, in
part, in the production of lactate. Although lactate does not
stimulate primary tumor growth in an in vivo breast cancer
model, it functions as a chemo-attractant in vitro and in vivo it
increases lung metastasis formation by 10-fold (54). The lactate-
induced migratory pattern was shown to depend on b1-integrin
expression (55), correlating with the metastatic behavior in a
variety of tumors (56). Moreover, b1-integrin interacts with
monocarboxylate transporter 4 (MCT4), a transporter
associated to lactate export, characteristic among metastatic
tumors, whose expression is regulated by hypoxia-inducible
factor 1-alpha (HIF-1a) (57). Both MCT4 and b1-integrin are
present at the leading edge of epithelial migrating cells (58).June 2021 | Volume 11 | Article 656851
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loss of MCT4 can modify integrin signaling, cell adhesion and
migration (61). In the other hand, the changes in pH
promoted by lactate stimulate the secretion and activation of
hydrolases, including cathepsins and MMP-9 that are known to
degrade ECM components and consequently decrease the
physical barrier permissive for invasion (62). In particular,
MMP-9 expression is correlated with survival and the
development of metastases in breast, ovarian and prostate
cancer (63–65). MMP-2 is also linked to metastasis, since itsFrontiers in Oncology | www.frontiersin.org 4upregulation by TGF-b2 is stimulated by lactate and increases
the migratory capacity of malignant glioma cells (66). The
increased lactate production is deeply related to increased
proliferation capacity of cancer cells and disease progression.
Thus, high concentrations of lactate in biopsies from breast,
colorectal, cervical, head and neck and lung cancers were
proposed to be indicative of increased metastatic potential
(67–70).
The increased expression of monocarboxylate transporter 1
(MCT1), another lactate transporter very well studied in cancer,FIGURE 2 | Main pathways involved in the metabolic remodeling of metastatic cancer cells, pivotal for energy and biomass production. Metastatic cancer cells are
metabolically more plastic than non-metastatic cancer cells, because they need to survive in primary tumor microenvironment, and they must also prosper in the
microenvironment of the metastasized organ. Glycolysis is a multi-step process, in which the expression of key glycolytic enzymes as hexokinase 2 (HK2) that
converts glucose in glucose-6-phosphate (G6P), 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) that promotes the conversion of fructose-6-
phosphate (F6P) in fructose-2,6-biphosphate (F2,6BP; an allosteric activator of the glycolytic enzyme phosphofructokinase 1 (PFK1)) and pyruvate by tumor M2-
pyruvate kinase (PKM2) that synthesizes pyruvate from phosphoenolpyruvic acid (PEP) have been showed to be involved in metastases establishment. Pyruvate is
an endpoint product of glycolysis that after its conversion into acetyl-CoA, which can alternatively be produced from acetate, under the action of acyl-coenzyme A
synthase short-chain family member 2 (ACSS2), then it will supply the tricarboxylic acid (TCA) cycle or the synthesis of fatty acids (FA). Additionality, FA can be
imported by CD36, being the FA pool deviated to FA b-oxidation (FAO). Glycolysis intermediate glucose-6-phosphate (G6P) can be diverged from glycolysis to
supply phosphate pentose pathway (PPP) through the action of glucose-6-phosphate dehydrogenase (G6PD), catalyzing the conversion of G6P into glucono-1,5-
lactone-6P (G1,5L6P) and generating nicotinamide adenine dinucleotide phosphate (NADPH). The 6-phosphogluconate dehydrogenase (6PGD) converts 6-
phosphogluconate (6PG) into ribose-5-phosphate (R5P), concomitantly with NAPDH production. Amino acids metabolism is crucial in biosynthesis and
bioenergetics. The serine and glycine syntheses and the one-carbon metabolism play a central role in cell metabolism. The action of serine hydroxymethyltransferase
(SHMT) catalyzes the conversion of serine into glycine, generating NADPH. NAPDH will be essential for the reduction of glutathione disulfide (GSSG) into glutathione
(GSH) by the action of glutathione reductase (GR). In turn, the oxidation of GSH in GSSG by glutathione peroxidase (GPx) is essential for the control of the redox
state of metastasizing cancer cells. Moreover, cysteine, glutamate and glycine are used in GSH synthesis. Glutamine catabolism through the action of glutaminase 1
(GLS1) leads to the production of glutamate and ammonia (NH3). In turn, glutamate dehydrogenase 1 (GLDH1) converts glutamate into a-ketoglutarate (a-KG) that
will fulfill TCA cycle. In mitochondria, glutamate is a target of glutamic-oxaloacetic transaminase 2 (GOT-2), producing a-ketoglutarate (a-KG) and aspartate, at the
expense of oxaloacetate (OAA). In cytoplasm, the action of GOT-1, at the expense a-KG, leads to glutamate production that can be converted into proline by the
action of proline dehydrogenase (PRODH). Moreover, pyrroline-5-carboxylate reductase (PYCR) catalyzes the inverse reaction, leading to the conversion of proline
into glutamate. Aspartate catabolism by asparagine synthetase (ASNS) promotes asparagine synthesis. Cysteine in cytoplasm is essential for GSH synthesis while in
mitochondria, its catabolism by the cystathionine-b-synthase (CBS) route; the cystathionine-g-lyase (CSE) route and the CAT/GOT:3-mercaptopyruvate
sulfurtransferase (MST) axis route leads to the production of pyruvate and hydrogen sulfide (H2S).June 2021 | Volume 11 | Article 656851
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activation of NF-kb pathway, which also regulates ECM
degradation and EMT induction (71). Therefore, silencing or
deleting MCT1 in vivo leads to the inhibition of cancer cell
migration, invasion and metastases formation (71). Accordingly,
in invasive bladder cell lines and in muscle-invasive bladder
cancer specimens, it was found a correlation between EMT
markers and high levels of lactate dehydrogenase A (LDHA)
expression, the enzyme that mainly converts pyruvate into
lactate in the end of glycolysis (72). Taken together, the
expression of crucial glycolytic interplayers accompanies the
phenotypical changes needed for EMT and metastasis.
Pentose Phosphate Pathway
The pentose phosphate pathway (PPP) is an important part of
glucose metabolism and, together with one-carbon metabolism
(73), a major source of NADPH, which is critical for countering
oxidative stress and maintain the metabolic flow (74). Thus, an
upregulation of PPP could support the survival of detached
metastasizing cells by neutralizing reactive oxygen species (ROS)
through NADPH generation (75). The detachment of anchorage-
dependent cells from the ECMcontributes to a decreased uptake of
glucose, which impairs PPP flux and induces high levels of ROS,
leading to anoikis, a formof apoptotic cell death (76).However, the
redox needs of metastatic cells depend on the microenvironment
of the secondary organ targeted by metastasis. Breast cancer
metastases are a good example, since brain metastases present
high expression levels of phosphate dehydrogenase (G6PDH)
and 6-phosphogluconolactonase, the enzymes from the oxidative
branch of PPP, together with high levels of glutathione
(GSH)-reductase and GSH S-transferase P (77), while bone
metastases present the opposite pattern of these enzymes
expression (78).
Mutated K-Ras has been described to drive the upregulation
of GLUT1, cell survival in low glucose conditions, and direction
of glycolytic metabolites down the non-oxidative branch of PPP
(79). The NADPH generated by the PPP will provide the cell
with ROS scavengers to control redox stress, particularly in
detached cancer cells, which contributes to anoikis resistance.
The oxidative and nonoxidative PPP were both found to be
activated in metastatic renal cancer, as seen by an increase in the
activity of G6PD and transketolase (TKT) (80), an enzyme that
regulates ribose 5-phosphate levels and de novo nucleotide
biosynthesis (81). However, in metastatic cancer cells, an
increase in the nonoxidative PPP compared to the oxidative
PPP was described due to an increase in TKT activity and TKT-
like-1 (TKTL1) protein overexpression (80). This may fulfill the
requirements for glycolytic intermediates and ribonucleotides in
highly proliferative cancer cells. In agreement, TKT was also
reported to be associated with metastasis of ovarian (82) and
esophageal (83) cancer.
Different types of cancer present the upregulation of PPP in
metastases in comparison to primary tumors, such as metastatic
renal cell carcinoma (84), melanoma (73) and pancreatic cancer
(85), in a way that involves not only metabolic adaptation but
also epigenetic remodeling (73, 85). As mentioned before, the
EMT controlling signaling pathways also regulate the glucoseFrontiers in Oncology | www.frontiersin.org 5metabolism, therefore under oxidative and metabolic stress,
Snail, a transcription factor that activates EMT (86), controls
the flux of glucose via the PPP to allow cancer cell survival and
enhanced metastatic potential (87).
Thus, genetic alterations in key metabolic genes accompanied
by microenvironment-conditioned oxidative stress, inducing
changes in the levels of ROS and NADPH, may contribute to
cancer progression and metastasis.Mitochondrial Metabolism and Redox
Balance
Several studies have shown that mitochondrial metabolism, in
particular, oxidation of various nutrients (such as compounds
derived from glutamine, glucose, and fatty acids) in the
tricarboxylic acid (TCA) cycle, is linked to cancer invasion,
being often upregulated in metastatic cancer cells (88, 89).
Although the TCA cycle generates important biosynthetic
intermediates that enable cancer cell proliferation, its principal
role in metastasizing cells is likely to be bioenergetics (90).
Metastasis requires that each disseminated cell has sufficient
energy to migrate and invade, while avoiding induced cell death
in circulation, attacks by the immune system, and even the
hostile microenvironment of the secondary site in distant
organs (91). Thus, the main obstacle to successful colonization
of a distal site by circulating cancer cells is survival, rather than
proliferation, since they might undergo anoikis, which is mainly
induced by low ATP levels resulting from a decrease in glucose
uptake in detached cells (92). Hence, metastatic cells can evade
anoikis through the upregulation of the TCA cycle to cope with
the decline in energy. Besides the one molecule of GTP produced
in the TCA cycle, the precursor molecules NADH and FADH2
are also produced, which are used to generate ATP via the
electron transport chain (ETC) and oxidative phosphorylation
(OXPHOS) (93). Some studies showed that fatty acids b-
oxidation feeds the TCA cycle with acetyl-CoA in order to
generate ATP (94, 95). Moreover, it is important to note that
biosynthesis is a process that consumes energy, requiring
significant amounts of ATP to synthesize macromolecules.
Some intermediates of the TCA cycle may contribute to
metastasis through epigenetic regulation. For instance, elevated
levels of a-ketoglutarate (a-KG) were described to maintain the
pluripotency of embryonic stem cells by global DNA
hypomethylation (96). As EMT is regulated by epigenetic
modulation and the EMT phenotype includes some stem-like
features, a-KG may play a similar role in this context (97).
Cancer cells usually present a deficient DNA demethylation
ability, which is commonly associated with decreased a-KG
levels and consequent alterations in a-KG-dependent
epigenetic enzymes, as DNA demethylation ten-eleven
translocation hydroxylases (TETs). In fact. Atlante et al., found
that targeting a-ketoglutarate dehydrogenase (KGDH), an
important TCA enzyme responsible for the oxidative
decarboxylation of a-KG to succinyl-CoA which promotes
increased levels of a-KG, is able to recover TETs ’
demethylation activity (98). TET expression stabilization by
increased a-KG bioavailability is further associated with theJune 2021 | Volume 11 | Article 656851
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nitric oxide (NO) levels, the latter with known inhibitory effect in
breast cancer progress (98, 99). KGDH inhibition impaired cell
invasion ability in vitro and in vivo reduced migration and
metastasis development in a metastatic breast cancer model (98).
TCA cycle intermediates succinate and fumarate tend to
accumulate as a result of mutations in succinate dehydrogenase
or fumarate hydratase, which lead to an upregulation of EMT-
related genes (100, 101). Moreover, mutations in isocitrate
dehydrogenases (IDHs) are also found to be related with EMT
occurrence. IDHs are responsible for the decarboxylation of
isocitrate to a-KG and are present in three isoforms: cytosolic
IDH1 and mitochondrial IDH2 and IDH3. Mutations in IDH1
and IDH2 are described in several tumors, including gliomas,
leukemia, breast and colorectal (102–106). These mutations in
IDH hinder the enzyme to carry out its forward normal reaction,
however, in a gain-of-function kind of way, it confers the enzyme
the ability to subsequently convert aKG to 2-hydroxyglutarate
(2-HG), an onco-metabolite that is found in high levels in
patients presenting IDH mutations (107, 108). 2-HG was
found to be an EMT inducer by affecting the ZEB1/miR-
200 axis, through epigenetic modifications in histones,
stimulating ZEB1, which is, by itself, a significant EMT
regulator; and by promoting down-regulation in the miR200
family, also associated to the EMT phenotype (103, 104).
Additionally, 2-HG was found to correlate with distant organ
metastasis in colorectal cancer (104).
OXPHOS is frequently upregulated in highly metastatic cells
in comparison to their less metastatic counterparts (109, 110), as
well as in circulating tumor cells compared to primary tumor
cells (111). For instance, through several cycles of adhesion
impairment of a non-tumorigenic melanocyte cell line,
Rodrigues et al. generated and selected stable clones displaying
a metastatic phenotype. These metastatic cells released high
amounts of glutamine catabolism-derived lactate, while
displaying an upregulated OXPHOS dependent on glutaminase
activity, with increased oxygen and succinate consumption and
enhanced fatty acids oxidation, which contributed to an augment
of ATP synthesis (109). Moreover, this was not accompanied by
an increase in mitochondrial content or biogenesis, reinforcing
the contribution of OXPHOS to the metastatic phenotype.
Others also showed that a mammary epithelial cancer cell line
exhibited enhanced OXPHOS, mitochondria biogenesis and
respiration via the transcription coactivator peroxisome
proliferator-activated receptor gamma, coactivator 1 alpha
(PGC-1a) (111). Accordingly, the role of OXPHOS was also
reinforced in another study, showing that melanoma cells
presenting a more metastatic phenotype were characterized by
an increased OXPHOS in comparison with melanocytes, and
when OXPHOS was impaired with Elesclomol (a drug shown to
alter the redox balance) no major effects were observed in
glycolysis (110). It has been shown that total abolishment of
OXPHOS inhibits metastasis but dysfunctional OXPHOS
surprisingly augments the metastatic behavior of cancer cells,
despite impaired respiration and energy production (112). This
is in agreement with the beneficial effect of increased glycolysisFrontiers in Oncology | www.frontiersin.org 6rates in metastatic cells. Another plausible explanation may be
the fact that OXPHOS produces ROS, which are essential to
mitochondria-orchestrated cell signaling and adaptation to stress
(113). Not only the activation and inhibition of mitochondrial
biogenesis, but also the mitochondrial overload and dysfunction
have been described to drive invasiveness of cancer cells (89, 111,
114), since it may activate the protein tyrosine kinases Src and
Pyk2, known to drive cancer cells motility by remodeling cell-cell
and cell-matrix interactions (89). Accordingly, the impairment
of mitochondrial redox homeostasis and administration of a
mitochondrial ROS scavenger has been shown to block cancer
progression in vivo, including metastasis formation (89, 115).
PGC1a was reported by LeBleu and colleagues as a metastatic
sponsor by stimulating mitochondrial biogenesis and OXPHOS
related genes, being expressed in circulating tumor cells,
probably supporting dissemination. This suggests that PGC1a
dysfunction may impact on the oxidative capacity of cancer cells
probably by altering the ETC efficacy and ATP production
capacity. Moreover, this study showed a significant correlation
between PGC1a expression and the formation of distant
metastases in human invasive breast cancer, associated with
OXPHOS promotion and mitochondrial biogenesis (111). In
prostate cancer, however, PGC1a was reported as a metastatic
suppressor, preventing tumor growth and metastasis
development through its oxidative metabolism-induced effects.
Nevertheless, inhibiting PGC-1a may result in contradictory
effects on cancer invasion, which could be related to the cancer
cell of origin and genetic drivers (20, 111, 114, 116). Moreover,
the expression of PGC-1a hinders prostate cancer progression
by activating catabolism via estrogen-related receptor alpha
(ERRa) (114). The same was observed in melanoma: PGC-1a
blocks the invasive capacity of cancer cells, and by knocking
down PGC-1a; invasiveness is rescued through the transcription
factor 4 (TCF4)–focal adhesion kinase (FAK) signaling axis, that
modulates cell–cell and cell–matrix interactions (116). These
contradictory and cancer-specific observation suggest that
metabolic rewiring may have different meanings in different
cancer contexts, depending on cancer cell needs, genetic
landscape and the overall tumor microenvironment (114).
Additionally, the oxidation of glutamine or fatty acids,
important substitutes of glucose, has been associated with
increased invasiveness and aggressiveness in breast, melanoma
and ovarian cancer (95, 109, 117). These findings may be
connected to cell motility programs as actin cytoskeleton
remodeling and contraction processes. Accordingly, these
processes require high energy demands and these can be fueled
by mitochondrial-produced ATP (20).
Regarding mitochondrial metabolism of glutamine and
glutamate, which will be depicted in the section Amino Acid
Metabolism, a study showed that invasive breast cancer cells were
able to secrete glutamate to induce the recycling of membrane
type 1 MMP (MT1-MMP) through metabotropic glutamate
receptor 3 (GRM3), thereby controlling the invasive capacity
(118). Glutamine-derived glutamate is a component of GSH
molecule to control the redox state, and an important source of
a−KG to fuel the TCA cycle (32). The expression of glutamineJune 2021 | Volume 11 | Article 656851
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ammonia (119), is associated with the suppression of
hepatocellular carcinoma metastasis (120), showing that the
glutamine bioavailability may be part of the metabolic rewiring
of metastatic cancer cells.
Cells that experience loss-of-attachment to the extracellular
matrix show an inhibition of glucose uptake and catabolism,
resulting in loss of cellular ATP. Successful intravasation and
extravasation during metastasis entail that cancer cells produce
or obtain more ATP through other ways (76, 121). Fatty acids
b-oxidation is an energy-efficient way to generate ATP to fulfill
the energy requirements of cancer cells (122). For instance,
metastatic ovarian cancer cells catabolize lipids obtained from
omental adipocytes to meet their high energy demands through
b-oxidation, which allows them to survive the colonization
process (123). Other examples of the involvement of b-
oxidation in the metastatic process are further described in the
section Fatty Acid Metabolism.
A well-balanced microenvironment is the key for metastasis
and ROS maintenance and scavenging through antioxidants,
which act as neutralizing-electron donors and are crucial for
cancer cell survival. ROS levels increase occurs by several
endogenous factors and mostly upon dysfunctional ETC
resultant from problems in OXPHOS or excess TCA cycle
activity, leading to increased mitochondrial byproducts of
oxygen metabolism. However, cancer cells can use this event
on their favor if these levels are not excessive and detoxifying
options are available. Moderate ROS levels are associated with
metastasis by inducing several mitochondrial signaling pathways
(113, 124–126). Antioxidants agents can be categorized as
enzymatic (as superoxide dismutase, catalase, thioredoxin
peroxidase and GSH peroxidases) or non-enzymatic (as
ascorbic acid and N-acetyl cysteine) (127). Superoxide
dismutase, for example, has been reported as an invasion
inducer, associating directly with increased metastasis, through
VEGF signaling (128–131). Overall, this antioxidant agent
partners with cancer cells, detoxifying an oxidative stress-rich
microenvironment with the goal of supporting cancer cells
proliferation and colonization capacity. ROS per se, when
present in non-lethal concentrations, can regulate the
activation of growth factors and integrins by different
processes, for example, the regulation of dynamics in the
cytoskeleton as a pro-metastatic agent (132). Moreover, it can
also rewire metabolic pathways as ERK1/2 activation, which is
upstream from STAT3 and HIF-1 (133).
Taken together, mitochondrial metabolism may act as a
double-edged sword, since it may be anti- or pro-metastatic,
depending on tumor context and on alterations in the activation
of different signaling pathways and redox conditions.
Amino Acid Metabolism
Amino acids are the building blocks of proteins, playing crucial
roles on the dynamic and homeostasis maintenance in cell
(patho)physiology. Much as the previous mentioned metabolic
pathways, amino acid metabolism is responsible for the supply of
intermediates, energy and other mediators, and share crossroadsFrontiers in Oncology | www.frontiersin.org 7with several metabolic trails, thus interfering with downstream
pathways, when altered.
Cancer cells exhibit unique demands, as for the specific amino
acid dependency that correlate with their malignant phenotype.
In fact, several amino acids have appeared to be in close relation
to tumorigenesis and to the metastatic process (134). Both
tyrosine and phenylalanine have long been studied within the
metastatic context and its restriction has shown anti-tumor
effects (135–137). Remarkably, Pelayo and colleagues reported
that tyrosine and phenylalanine restriction affected the
metastatic potential of cancer cells by impacting across the
overall process of invasion via inhibition of the Ras/Rho
pathway, the latest, per se, being an important signaling
pathway for the binding of integrins to the ECM (138).
Tyrosine was proposed as a possible therapy option in
metastatic cancer treatment by Gueron et al. This metabolite
showed anti-proliferative effects and impaired tumor growth in
metastatic prostate cancer models, without known toxic effects.
This work shows that tyrosine induced autophagy in PC3 cells,
impairing STAT3/NFkB/Notch pathway. Moreover, tyrosine
abolished the formation of metastasis in breast cancer models.
However, this study also reveals phenylalanine as capable of
reverting tyrosine effects (139).
Glutamine is an important non-essential amino acid, highly
abundant in the bloodstream and of great preference of tumors,
being, thus, present in low concentration in the latter (136, 137).
Moreover, this amino acid is essential in tumor progression,
given its role in interorgan ammonia transport maintenance
among proliferating cells (140). Glutamine is the precursor of
glutamate, an equally important amino acid across metabolism,
displaying many functions. For this matter, we will focus on the
glutamine-glutamate axis role as a supplier for TCA and for the
production of GSH, a tripeptide composed by glutamate,
cysteine and glycine, which is the main cellular ROS scavenger
(75). Glutaminase 1 and 2 (GLS-1 and -2) are responsible for the
conversion of glutamine into glutamate, which is subsequently
converted by NADP(+)-dependent glutamate dehydrogenase 1
and 2 (GDH1 and -2) into a-KG. While GLS-1 expression is
associated with ovarian cancer invasiveness, GDH1 expression is
reportedly associated with colorectal cancer metastasis, both
mainly by supplying the TCA and activating the signal
transducer STAT3 (117, 141). STAT3 regulates EMT, cell
migration and invasion, and is also indirectly related to
hypoxia-related cancer metabolic remodeling, under the
control of HIF-1a (142). Moreover, glutamate is also a
substrate for glutamic-oxaloacetic transaminase 1 and 2
(GOT-1 and -2), resulting a-KG and aspartate, at the expense
of oxaloacetate (143). GOT-2 is directly regulated by STAT3 in
lymphoma (144), but few studies have focused on the role of any
form of GOT in metastasis. However, given the pro-metastatic
roles of STAT3 (145–149), GOT-2 may be related to the pro-
metastatic effects of STAT3. Moreover, GOT-1 and -2 also
display a cysteine aminotransferase (CAT) activity, catalyzing
the transamination of cysteine to 3-mercaptopyruvate and
glutamate (143). Cysteine is an amino acid, which has three
main associated catabolic routes: the cystathionine-b-synthaseJune 2021 | Volume 11 | Article 656851
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mercaptopyruvate sulfurtransferase (MST) axis; all of them
producing H2S concomitantly with cysteine degradation. H2S
is a gasotransmitter with both physiologic and pathophysiologic
effects, depending on its availability in the microenvironment.
Increased H2S generation is reported as a tumor bioenergetics
stimulator, leading to increased ATP production by OXPHOS
and glycolysis. Moreover, it is also reported as a neoangiogenesis
p romote r v ia PI3K/Ak t and MAPK pa thways , a
chemoresistance inducer and it is, by itself a powerful
antioxidant (150, 151). Wang et al. reported that induced H2S
secretion by increased expression of CTH (gene encoding CSE)
led to activation of IL-1b/NF-kb pathway, which directly
correlated with increased prostate cancer cell invasion. This
study further indicates that knocking down CTH decreased
metastasis, an effect that, as expected, was reverted by
overexpressing CTH, indicating a pro-tumoral and pro-
metastatic role of cysteine catabolism and H2S production in
prostate cancer (152). Likewise, CBS has been reported to
promote similar effects. Bhattacharyya and colleagues showed
that CBS silencing had inhibitory effects on ovarian cancer cells
proliferation, in peritoneal metastatic development and in
resistance to cisplatin (153). Alongside, Wang et al. reported
that CBS overexpression in hepatocellular carcinoma was
associated with lack of sensitivity to doxorubicin (154). The
downregulation of these enzymes consequently promotes a
decrease in GSH and H2S production, important regulators of
oxidative stress, and inhibits pathways such as NF-kB, relevant
in cancer metastasis (153, 154).
The expression of asparagine synthetase (ASNS), the enzyme
that generates asparagine from aspartate, is further reported as
being enhanced in primary tumors and correlated with
metastatic relapse (155). ASNS knock down or dietary
asparagine restriction reduced metastasis and cancer progression
while increased dietary asparagine or overexpression of
asparagine synthetase drove metastatic progression (155).
Asparagine stimulates the expression of GS, which is an
important controller of glutamine requirements (119). Changing
the availability of asparagine influenced the invasive potential of
cancer cells through the increased expression of EMT genes
(155). An interconnective regulation of asparagine and
glutamine metabolism dependent on these amino acids’
availability is stated to be responsible for the control of cancer
cells proliferation, evasion to apoptosis, migration/invasion and
metastasis (156).
S e r i n e and g l y c i n e h a v e a t i gh t l i nk : s e r i n e
hydroxymethyltransferases can reversibly convert serine into
glycine in the context of the one-carbon metabolism. This
conversion releases NADPH, and thus, can be beneficial in a
metastatic context by balancing microenvironment redox and
protecting cancer cells from oxidative stress, which is reinforced
by the role of glycine as a component of GSH. These amino acids
are additionally reported as epigenetic modulators in cancer cells
through the contribution for the one-carbon metabolism and the
synthesis of intermediates to supply DNA and RNA methylation
(75, 157).Frontiers in Oncology | www.frontiersin.org 8Proline has been described as a relevant amino acid, playing a
role in the different steps of cancer progression and metastasis,
mainly through the proline metabolic cycle dependent on
NADPH (158). In breast cancer, increased levels of proline
de novo synthesis coincide with metastatic cellular phenotype
(159). Accordingly, studies suggest that proline metabolism,
through proline dehydrogenase (PRODH) and proline
dehydrogenase reductase (PYCR), is associated with breast
cancer metastasis, being upregulated in metastases compared
to primary breast cancer tumors (160, 161). Actually, in proline
catabolism, PRODH activity generates ROS, which are able to
promote metastasis through several mechanisms, such as
upregulation of glycolysis (through HIF1-a), activation of
several signaling cascades involved in survival (such as the
MAPK, NF-kB, PI3K), induction of EMT (e.g. increase
vimentin expression) and induction of angiogenesis (162).
Moreover, the resultant product of proline oxidation pyrroline-
5-carboxylate (P5C) can be converted into glutamate by
pyrroline-5-carboxylate dehydrogenase (P5CDH), which can
then be converted into a-KG, fueling the TCA cycle (163,
164). Therefore, proline can contribute for metastasis with
ATP, ROS and the synthesis of other macromolecules.
Furthermore, proline was described as an epigenetic regulator
in embryonic stem cells, leading to a migratory and invasive
mesenchymal phenotype, possibly by interfering with
methylation status, thus modulating gene expression (165).
Comes and colleagues showed that L-proline is able to induce
an embryonic-stem-cell-to-mesenchymal-like transition by
embryonic stem cell transcriptome rewiring towards a motile,
invasive and highly migratory pluripotent phenotype. This work
shows that increased methylation levels in H3K9 and H3K36
seem to underly this remodeling, being the methylation status a
key in the balance of this switch. In line with this, L-proline
withdrawal or ascorbic acid (vitamin C) addition, a known
cofactor for H3K9 jumonji demethylases (166) with regulatory
roles in stem cell differentiation and somatic cell reprogramming
(167, 168), reverts this process escorted by H3K9 and H3K36
demethylation (165). Moreover, vitamin C was also associated
with pro-oxidant effects, via high ROS production (169), and
while specific doses are able to stop cancer cell glycolysis and
affect metastasis (170), recent studies have shown a role in
metastasis promotion, being able to regulate cancer stem cells
and affect extracellular matrix (171).
Fatty Acid Metabolism
Nowadays, it is well known that fatty acid synthesis and uptake
plus b-oxidation are associated with cancer progression. Both
fatty acid uptake and accumulation have been shown to augment
the invasiveness, migration, and progression of different types of
cancer, such as liver and breast carcinomas (172, 173).
Particularly, hepatocellular carcinoma progression was
correlated with CD36/fatty acid translocase and high free fatty
acid levels via induction of EMT, which was promoted by TGF-b
andWnt signaling (172). Fatty acid transport protein 1 (FATP1),
a member of the FATP/SLC27 protein family, which increases
the cellular uptake of long-chain fatty acids (174), has beenJune 2021 | Volume 11 | Article 656851
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involved in metastasis. Considering breast cancer patients and
using data from the TCGA database, it was observed that
metastases expressed higher levels of FATP1/SLC16A1 when
comparing to normal breast tissue (175). In addition, in
melanoma patients, the expression of FATP1 was found to be
higher in subcutaneous metastases when compared to primary
tumors (176).
Fatty acids mobilized from lipid stores may be degraded in the
mitochondria through b-oxidation to provide energy when
necessary (177). In the b-oxidation pathway, acyl-CoAs are
cyclically dehydrogenated, hydrated, and decarboxylated,
leading to the progressive shortening of the fatty acid, together
with the generation of NADH and FADH2 and acetyl-CoA (178).
NADH and FADH2 will be used for ATP production in the ETC,
and acetyl-CoA can enter the TCA cycle (178). Besides providing
energy when glucose becomes limiting, b-oxidation also controls
the oxidative stress by increasing the intracellular levels of
NADPH (179). b-oxidation was reported as crucial for the
survival of cells from solid tumors when undergoing loss-of-
attachment, which leads to anoikis or cell death due to oxidative
stress (121, 180). Enhanced b-oxidation has been described in
metastatic breast cancer (75, 181), and in metastatic triple
negative breast cancer (TNBC) the knock down of carnitine
palmitoyltransferases, important elements in the carnitine
shuttle of fatty acids into the mitochondria, led to the
inhibition of the c-Src proto-oncogene and Src-mediated
metastas is (75, 94) . Hal ldorsson et al . , performed
metabolomics profiling of a breast epithelial cell line and its
EMT derived mesenchymal variant and showed that
b-oxidation, driven by peroxisome proliferator-activated
receptor (PPAR), fueled the mesenchymal phenotype while
glycolysis and OXPHOS were more active in the epithelial
phenotype (182). Accordingly, an upregulation of b-oxidation
was observed in colon cancer cell co-cultured with adipocytes
and it was linked with EMT induction as indicated by reduced
E-cadherin but increased vimentin expression (183, 184).
Fatty acid synthase (FASN) is the enzyme involved in
endogenous fatty acid synthesis (185), which is crucial for the
formation of membrane lipids and sustains redox equilibrium
and the relative levels of saturated and unsaturated fatty acids in
cancer cells (185). FASN has been shown to play a role in tumor
invasion and metastasis, and FASN inhibition or knockdown
reduced liver metastasis of colorectal cancer (186). The
inhibition of FASN expression abolished the invasion and
migration of HCC cells, demonstrating the contribution of
FASN to malignant hepatocellular carcinoma metastasis (187).
Additionally, FASN expression induced peritoneal metastasis of
ovarian cancer through the induction of EMT (188).
Acetyl-CoA can be synthesized in different metabolic
pathways (32, 189) and it is an important donor for protein
and histone acetylation (190), as well as the main compound
initiating the TCA cycle, the building block in fatty acid synthesis
and the final product of fatty acids b-oxidation. Inhibiting the
lipogenic enzyme acetyl-CoA carboxylase 1 (ACC1) results in
the accumulation of acetyl-CoA, which activates an EMTFrontiers in Oncology | www.frontiersin.org 9program through Smad2 transcription factor acetylation and
subsequently induction of breast cancer cell invasion and
metastasis (191).
Acetyl-CoA can also be synthesized from acetate under the
action of acetyl-CoA synthetase 2 (ACSS2), being further used in
fatty acids synthesis and TCA cycle. ACSS2 silencing leads to
deacetylation of HIF-2a during hypoxia, which in turn results in
HIF-2a-dependent EMT activation (192). These findings
indicating that acetyl-CoA favors metastasis are in agreement
with the results obtained in patient-derived xenograft melanoma
models, showing that metastatic tumors presented high levels of
metabolites related to histone methylation, including acetyl-CoA
(193). Moreover, in these models, the inhibition of histone
methylation blunted invasiveness and metastatic spread (193),
resembling the inhibition of acetyl-CoA synthesis and showing
again that the epigenetic remodeling needed for the display of the
metastatic phenotype is tightly related to metabolic rewiring.FROM PRIMARY TUMOR TO
METASTASIS: METABOLIC
COMPARISON
Over the last years, cancer metabolism gained an increasing
research interest, though this was mainly focused on the primary
tumor, while little is known about the metabolic remodeling that
occurs during metastasis. Different organs in the human body
present characteristic metabolic features (194), thus it is evident
that metastatic subclones exhibit different phenotypes when
compared to the primary tumor, according to the particular
microenvironment of the organ. The deepening of this
knowledge and the extensive characterization of the distinction
between primary tumor and metastases metabolism is crucial for
the development of new therapeutic strategies.
Dupuy et al. used a murine nonmetastatic breast cancer cell
line and compared its metabolic profile with metastatic cell
populations from the same parental tumor (195). The
metastatic subclones were characterized by an increased
utilization of pyruvate and glucose, as well as a greater
oxidative capacity, resulting in increased glycolysis and
OXPHOS. In this study, distinct cell populations that
preferentially colonize the bone, lung, or liver presented
characteristic metabolic changes, mainly regarding glucose
utilization. While bone and lung metastasis engaged OXPHOS,
glycolysis-dependent metabolic strategies were favored by liver-
metastatic cells, viaHIF-1a and PDK1. Moreover, bone and lung
metastatic cells displayed increased glutamine uptake, which
reflected in increased levels of glutamine-derived citrate and
succinate, TCA cycle intermediates. These findings are of
extreme importance since the understanding of these divergent
metabolic profiles may contribute to the development of targeted
therapies. Since then, several articles reinforced the importance
of this comparison. Li and colleagues showed an upregulation of
mitochondrial serine and one-carbon metabolism in metastatic
subclones of TNBC cell line (MDA-MB-231), comparing to theJune 2021 | Volume 11 | Article 656851
Hipólito et al. Targeting Metabolism in Metastatic Cellsnonmetastatic cells (196). This pathway is involved in
proliferation, through de novo purine synthesis (197), and its
impairment suppressed proliferation in vitro and impaired the
growth of lung metastases in mice models, being correlated with
poor survival of human breast cancer patients (196).
Consistent with these results, distinct metabolic profiles were
revealed between non-metastatic and metastatic cells of human
R-18 melanoma cell line (established from a xenograft model) by
proton high resolution magic angle spinning magnetic resonance
spectroscopy (1H-HR-MAS-MRS) (198). The metastatic tumors
expressed higher levels of phosphocholine, creatine, and glycine,
while lower levels of lactate were observed. These alterations in
creatine and choline metabolism were consistent with a similar
study using a B16F10 murine melanoma cell line, being these
metabolites important for tumor progression and the
development of liver and lung metastases (199). Moreover,
while there is substantial evidence that the primary tumor is
characterized by high lactate levels, favoring the release of
metastatic cells, lactate production by metastases is not well
stablished. For instance, Xu and colleagues used a breast
carcinoma (MDA-MB-231) xenograft model and by using
hyperpolarized 13C-pyruvate NMR spectroscopy found out that
less metastatic breast tumors produced more lactate than the
highly metastatic tumors (200). On the other side, Lemma et al.
observed the release of large amounts of lactate from bone
metastatic breast cancer cells when compared with non-
osteotropic ones, promoting the formation of osteolytic
lesions (201).
The wide variety of metabolic pathways supporting cancer
invasion makes it challenging to design new effective therapeutic
approaches. Besides, cancer cells dissemination to distant organs
may be an early event that may occur before the initial diagnosis,
thus the time frame for treatment targeting cancer invasiveness
will be limited (202). Focusing on the metabolic changes that
take place in primary tumors will likely be more useful to predict
metastatic risk.
Metabolic Targeting Encloses the Success
of the Treatment of Metastatic Disease
Here we reviewed the impact of metabolism in metastatic cell
characteristics, being this metabolic plasticity essential during
cancer progression. Tumor cells have the capacity to use
metabolites from the microenvironment for its own benefit,
thus coping with the challenging conditions faced during the
metastatic cascade (Figure 3). Therefore, targeting the
metabolism of metastases could be a good strategy to tackle
metastatic cancer.
Since glycolysis is upregulated in metastases, the use of
inhibitors for key enzymes could be effective. Cheng and
colleagues modified lonidamine, a HK2 inhibitor with limited
efficacy, to mitochondria-targeted mito-lonidamine. This new
inhibitor was more potent, able to inhibit OXPHOS and
mitochondrial energetics in lung cancer cells, inducing
autophagy-related cell death, decreasing the viability, growth,
and brain metastasis of lung cancer xenograft mice models (203),
without causing toxicity. Another HK2 inhibitor is 2-deoxy-D-Frontiers in Oncology | www.frontiersin.org 10glucose (2-DG) (204), a non-metabolizing synthetic glucose
analog able to abolish ATP generation (205, 206). This analog
is able to cross the brain-blood barrier, being a good candidate to
target brain metastases (207). Therefore, a phase I dose-
escalation trial (NCT00096707) evaluated the effect of 2-DG
alone or combined with docetaxel in patients with histologically
or cytologically confirmed locally advanced or metastatic solid
tumors. A potential application as an adjuvant therapy was
found, although its clinical use implies several side effects
(208). Nevertheless, a study showed that 2-DG treatment
resulted in effective migration and invasion inhibition of an
invasive subclone of a TNBC cell line, through targeting
glycolysis (209). Therefore, blocking invasiveness can be a new
strategy to target tumor metastasis. Moreover, 2-DG treatment
also resulted in decreased proliferation, colony formation,
migration and invasion, and decreased expression of EMT-
related genes, including quinone oxidoreductase-1-induced
vimentin, Snail, Slug and Twist, and upregulation of E-
cadherin (210).
Another glycolysis key enzyme is PFKFB3 and its blockage
with the phosphatase inhibitor 3PO in endothelial cells resulted
in tumor vessel normalization and impaired metastasis (53, 211).
This enzyme is usually overexpressed in cancer, and its inhibition
with 1-(4-pyridinyl)-3-(2-quinolinyl)-2-propen-1-one (PFK15)
blocked glycolysis and suppressed cell proliferation, motility
and induced apoptosis of head and neck squamous cell
carcinoma cells (212). Also, in vivo data from metastatic niche
models showed that PFK15 decreased lung metastases and
extended life expectancy in mice (212). Currently, a derivative
of 3PO, ACT-PFK-158, is under phase I clinical trial
(NCT02044861) for advanced solid malignancies, as a
monotherapy (213).
As mentioned above, IDH 1/2 are enzymes involved in the
TCA cycle. When these enzymes are mutated, they use a-KG as a
substrate to produce the oncometabolite 2-HG (214). Several
clinical trials have been pursuing a strategy to inhibit 2-HG
production. Several studies using IDH1R132C mutant inhibitors,
such as AGI-5027 (215) and AGI-5198 (216), sustain a potential
use to target metastasis, once they affect pathways involved in the
metastatic cascade, such as mTOR pathway (217). Several clinical
trials are currently active (NCT02073994, NCT02989857,
NCT02074839, NCT04195555) to evaluate AG-120 (IDH-
mutant inhibitor) efficacy and safety in several cancer types,
being this already FDA-approved for IDH-mutant relapsed or
refractory acute myeloid leukemia (218, 219). However, this
therapy can be a double-edge sword, since IDH mutant tumors
are less proliferative and invasive than IDH wild-type
tumors (140).
Jin and colleagues showed that omeprazole inhibited MDA-
MB-231 breast cancer cell invasion in vitro and lung metastasis
in a mouse model, alongside with decreased expression of two
prometastatic genes, MMP-9 and C-X-C chemokine receptor 4
(CXCR4) (220). It is known that FASN is inhibited by
omeprazole (221, 222) and, currently, a phase 2 clinical trial is
evaluating the use of omeprazole to improve the efficacy of
neoadjuvant chemotherapy in breast cancer (NCT02595372).June 2021 | Volume 11 | Article 656851
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to reduce tumor lung metastases (53.4%) in C57BL/6 mice
subcutaneously injected with melanoma B16-F10 cells (223).
Interrupting the mechanisms of lipid uptake through the
pharmacological inhibition of FATP1 with arylpiperazines
(224) represents a promising therapeutic strategy for breast
cancer and melanoma, as this protein is overexpressed in these
tumors (175, 176). Although the effect of arylpiperazines on
invasion and metastasis has not been studied yet, the inhibition
of FATP1 with arylpiperazines interfered with the uptake of fatty
acids and cell viability of breast cancer cells (175).
More studies are needed to expand the knowledge but
mapping the alterations upon the metabolic drift cancer cells
undergo, enabling metastasis, is a profitable field to identify new
targets towards personalized medicine in cancer treatment.HIGHLIGHTS
Even though metastasis is a widely researched field, there is still a
lot to understand about the metastatic processes, the genetic and
metabolic profile, and essentially what incites cancer cells to
metastasize. There is a wide variety of metabolic alterations
related to cancer metastasis, either in the primary tumor or in
the metastatic tumor. Defining the metabolic profile in each step
of the metastatic cascade would provide clues to the
requirements needed for a metabolism-based therapy.Frontiers in Oncology | www.frontiersin.org 11Although several preclinical studies have been made, there is a
lack of clinical trials evaluating the effect of several therapies in
metastatic cancer, aiming to incorporate them into the standard
of care. In the future, taking the tumor microenvironment into
consideration will also contribute to the identification of new
molecular targets to suppress metabolic crosstalk pivotal to
facilitate the adaptive process of cancer cells to different
microenvironments and consequently to sustain their survival.AUTHOR CONTRIBUTIONS
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22. Massagué J, Obenauf AC. Metastatic Colonization by Circulating Tumour
Cells. Nature (2016) 529:298–306. doi: 10.1038/nature17038Frontiers in Oncology | www.frontiersin.org 1223. Nieswandt B, Hafner M, Echtenacher B, Männel DN. Lysis of Tumor Cells
by Natural Killer Cells in Mice is Impeded by Platelets. Cancer Res (1999)
59:1295–300.
24. Schlesinger M. Role of Platelets and Platelet Receptors in Cancer Metastasis
06 Biological Sciences 0601 Biochemistry and Cell Biology. J Hematol Oncol
(2018) 11:1–15. doi: 10.1186/s13045-018-0669-2
25. Labelle M, Begum S, Hynes RO. Direct Signaling Between Platelets and
Cancer Cells Induces an Epithelial-Mesenchymal-Like Transition and
Promotes Metastasis. Cancer Cell (2011) 20:576–90. doi: 10.1158/1538-
7445.FBCR11-PR1
26. Schumacher D, Strilic B, Sivaraj KK, Wettschureck N, Offermanns S.
Platelet-Derived Nucleotides Promote Tumor-Cell Transendothelial
Migration and Metastasis Via P2Y2 Receptor. Cancer Cell (2013) 24:130–
7. doi: 10.1016/j.ccr.2013.05.008
27. Bendas G, Borsig L. Cancer Cell Adhesion and Metastasis: Selectins,
Integrins, and the Inhibitory Potential of Heparins. Int J Cell Biol (2012)
2012:1–10. doi: 10.1155/2012/676731
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